( and academic research sectors as the n...)UW-Madison dean predicts bio-economy will fuel Wisconsin
Navigation Links
| HOME >> BIOLOGY >> TECHNOLOGY |
UW-Madison dean predicts bio-economy will fuel Wisconsin
and academic research sectors as the natural components of a bio-economy, and she believes the raw material from agriculture and forestry will help the state make the transition from corn-based ethanol to the next generation represented by cellulosic ethanol.
This "G2" ethanol will be produced from naturally abundant biomass material - crops and crop residue, forest residue, grasses, and......
Full article >>>
'"/>
Source:wistechnology.com By Joe Vanden Plas 02/14/07
Related biology technology :
1. UW-Madison to receive $125M for bioenergy research center
2. Three finalists named for UW-Madison CIO
3. UW-Madison launches new high-speed research network
4. UW-Madison approves new research institute
5. Scott Converse, UW-Madison School of Business, on the innovation mind-set
6. Scott Converse, UW-Madison School of Business, on IT workforce development
7. UW-Madisons Beebe wins scientific award
8. UW-Madison MBA program ranked among best for investment return
9. UW-Madison gets $333,000 for biofuels research
10. UW-Madison enters Kauffman grant competition
11. WARF, UW-Madison seek designer for the Wisconsin Institutes for Discovery
Post Your Comments:
Breaking Biology Technology:EUCODIS Bioscience Appoints Thomas Fischer as New CEO 2Merrimack Pharmaceuticals Acquires Hermes Biosciences, Inc. 2Merrimack Pharmaceuticals Acquires Hermes Biosciences, Inc. 3RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 2RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 3RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 4RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 5RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 6Stemline Therapeutics Announces Poster Presenting in vivo and Anti-Cancer Stem Cell Activity of SL-401 against Chronic Myeloid Leukemia (CML) at the 51st Annual Meeting of the American Society of Hematology (ASH) 2
[0] EUCODIS Bioscience Appoints Thomas Fischer as New CEO[0] Merrimack Pharmaceuticals Acquires Hermes Biosciences, Inc. [0] RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE)[0] Stemline Therapeutics Announces Poster Presenting in vivo and Anti-Cancer Stem Cell Activity of SL-401 against Chronic Myeloid Leukemia (CML) at the 51st Annual Meeting of the American Society of Hematology (ASH)
Other Biology Technology:LifeNet Health Chief Scientific Officer Wins Award 2BioCryst Reports First Quarter 2008 Financial Results and Clinical Update 2BioCryst Reports First Quarter 2008 Financial Results and Clinical Update 3BioCryst Reports First Quarter 2008 Financial Results and Clinical Update 4BioCryst Reports First Quarter 2008 Financial Results and Clinical Update 5BioCryst Reports First Quarter 2008 Financial Results and Clinical Update 6BioCryst Reports First Quarter 2008 Financial Results and Clinical Update 7BioCryst Reports First Quarter 2008 Financial Results and Clinical Update 8
Breaking Biology News(10 mins):Papillomavirus silences innate immune response 2Species down, disease up 2Species down, disease up 3Species down, disease up 4AGU fall meeting: Preliminary press conference topics, press pre-registration deadline 2AGU fall meeting: Preliminary press conference topics, press pre-registration deadline 3AGU fall meeting: Preliminary press conference topics, press pre-registration deadline 4AGU fall meeting: Preliminary press conference topics, press pre-registration deadline 5AGU fall meeting: Preliminary press conference topics, press pre-registration deadline 6Zix Corporation Addresses New HIPAA Regulations 49867 1Zix Corporation Addresses New HIPAA Regulations 49867 2Zix Corporation Addresses New HIPAA Regulations 49867 3Report 3A Primary Care Doctors in Greatest Demand 49865 1Report 3A Primary Care Doctors in Greatest Demand 49865 2Fertility Information Will Enhance Reproductive Health Awareness 49863 1
Other Biology News:The brain's executive is an 'event planner' 2Finding paves way for better treatment of autoimmune disease 2Basic work on E. coli identifies two new keys to regulation of bacterial gene expression 2Basic work on E. coli identifies two new keys to regulation of bacterial gene expression 3
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |